The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors
Open accessAbstract
OBJECT: The authors sought to determine the incidence, time course, and risk factors for overall adverse radiation effect (ARE) and symptomatic ARE after stereotactic radiosurgery (SRS) for brain metastases. METHODS: All cases of brain metastases treated from 1998 through 2009 with Gamma Knife SRS at UCSF were considered. Cases with less than 3 months of follow-up imaging, a gap of more than 8 months in imaging during the 1st year, or inadequate imaging availability were excluded. Brain scans and pathology reports were reviewed to ensure consistent scoring of dates of ARE, treatment failure, or both; in case of uncertainty, the cause of lesion worsening was scored as indeterminate. Cumulative incidence of ARE and failure were estimated with the Kaplan-Meier method with censoring at last imaging. Univariate and multivariate Cox proportional hazards analyses were performed. RESULTS: Among 435 patients and 2200 brain metastases evaluable, the median patient survival time was 17.4 months and the median lesion imaging follow-up was 9.9 months. Calculated on the basis of 2200 evaluable lesions, the rates of treatment failure, ARE, concurrent failure and ARE, and lesion worsening with indeterminate cause were 9.2%, 5.4%, 1.4%, and 4.1%, respectively. Among 118 cases of ARE, approximately 60% were symptomatic and 85% occurred 3–18 months after SRS (median 7.2 months). For 99 ARE cases managed without surgery or bevacizumab, the probabilities of improvement observed on imaging were 40%, 57%, and 76% at 6, 12, and 18 months after onset of ARE. The most important risk factors for ARE included prior SRS to the same lesion (with 20% 1-year risk of symptomatic ARE vs 3%, 4%, and 8% for no prior treatment, prior whole brain radiotherapy [WBRT], or concurrent WBRT) and any of these volume parameters: target, prescription isodose, 12-Gy, or 10-Gy volume. Excluding lesions treated with repeat SRS, the 1-year probabilities of ARE were < 1%, 1%, 3%, 10%, and 14% for maximum diameter 0.3–0.6 cm, 0.7–1.0 cm, 1.1–1.5 cm, 1.6–2.0 cm, and 2.1–5.1 cm, respectively. The 1-year probabilities of symptomatic ARE leveled off at 13%–14% for brain metastases maximum diameter > 2.1 cm, target volume > 1.2 cm 3, prescription isodose volume > 1.8 cm 3,12-Gy volume > 3.3 cm 3, and 10-Gy volume > 4.3 cm 3, excluding lesions treated with repeat SRS. On both univariate and multivariate analysis, capecitabine, but not other systemic therapy within 1 month of SRS, appeared to increase ARE risk. For the multivariate analysis considering only metastases with target volume > 1.0 cm 3, risk factors for ARE included prior SRS, kidney primary tumor, connective tissue disorder, and capecitabine. CONCLUSIONS: Although incidence of ARE after SRS was low overall, risk increased rapidly with size and volume, leveling off at a 1-year cumulative incidence of 13%–14%. This study describes the time course of ARE and provides risk estimates by various lesion characteristics and treatment parameters to aid in decision-making and patient counseling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaw, E., Scott, C., Souhami, L., Dinapoli, R., Kline, R., Loeffler, J., & Farnan, N. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00507-6 · Cited by 1,608
Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis
Minniti, G., Clarke, E., Lanzetta, G., Osti, M. F., Trasimeni, G., Bozzao, A., Romano, A., & Enrici, R. M. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-48 · Cited by 828
Flickinger, J. C., Kondziolka, D., Lunsford, L. D., Kassam, A., Phuong, L. K., Liscak, R., & Pollock, B. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00513-1 · Cited by 382
Korytko, T., Radivoyevitch, T., Colussi, V., Wessels, B. W., Pillai, K., Maciunas, R. J., & Einstein, D. B. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.07.980 · Cited by 324
Chin, L. S., Ma, L., & DiBiase, S. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.94.6.0899 · Cited by 184
Self-citationBarker, F. G., Butler, W. E., Lyons, S., Cascio, E., Ogilvy, C. S., Loeffler, J. S., & Chapman, P. H. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.2.0254 · Cited by 80
Predicted Dose-Volume Isoeffect Curves for Stereotactic Radiosurgery with the 60 Co Gamma Unit
Flicktnger, J. C., Lunsford, L. D., Wu, A. E., & Kalend, A. M. (1991) · Acta Oncologica · doi:10.3109/02841869109092387 · Cited by 29
Cited by
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain
Milano, M. T., Grimm, J., Niemierko, A., Soltys, S. G., Moiseenko, V., Redmond, K. J., Yorke, E., Sahgal, A., Xue, J., Mahadevan, A., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.08.013 · Cited by 402
Kaufmann, T. J., Smits, M., Boxerman, J., Huang, R., Barboriak, D. P., Weller, M., Chung, C., Tsien, C., Brown, P. D., Shankar, L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa030 · Cited by 267
Jalalifar, S. A., Soliman, H., Sahgal, A., & Sadeghi-Naini, A. (2022) · Cancers · doi:10.3390/cancers14205133 · Cited by 15
Metadata
- Authors
- Sneed, P. K., Mendez, J., Vemer-van den Hoek, J. G. M., Seymour, Z. A., Ma, L., Molinaro, A. M., Fogh, S. E., Nakamura, J. L., & McDermott, M. W.
- Venue
- Journal of Neurosurgery
- Published
- 2015-08
- Volume
- 123
- Issue
- 2
- Pages
- 373-386
- ISSN
- 0022-3085 (ISSN-L)
- 1933-0693
- OpenAlex
- W1872520013
- Cited by
- 352
- References
- 7
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. https://app.cochat.ai/papers/10.3171/2014.10.jns141610
- The paper
- Sneed, P. K., Mendez, J., Vemer-van den Hoek, J. G. M., Seymour, Z. A., Ma, L., Molinaro, A. M., Fogh, S. E., Nakamura, J. L., & McDermott, M. W. (2015). Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Journal of Neurosurgery. https://doi.org/10.3171/2014.10.jns141610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.